EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), a Boston-based
biopharmaceutical company focused on the global development and
commercialization of biosimilar monoclonal antibodies, today announced
that the Company is scheduled to present a corporate overview at the
Leerink Global Healthcare Conference in New York City on Thursday,
February 12, 2015 at 11:35 a.m. Eastern Time.
Links to a live audio webcast and replay of the presentation may be
accessed on the EPIRUS website events page at http://ir.epirusbiopharma.com/events.cfm.
About EPIRUS Biopharmaceuticals, Inc.
EPIRUS Biopharmaceutical (NASDAQ: EPRS) is global biosimilar company
focused on improving patient access to important medicines. EPIRUS’
operationally synergistic pipeline of biosimilar product candidates
includes BOW015
(infliximab), BOW050
(adalimumab) and BOW070
(tocilizumab). The reference products for these product candidates –
Remicade®, Humira® and Actemra®, respectively – together generated over
$20 billion in global sales in 2013. The Company’s strategy for
commercial success and profitability relies on targeted approaches for
diverse and competitive global markets.
More information about EPIRUS can be found at www.epirusbiopharma.com.
Remicade is a registered trademark of Johnson and Johnson (www.jnj.com)
Humira is a registered trademark of AbbVie (www.abbvie.com)
Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha
Corp., a member of the Roche Group (www.gene.com)
Copyright Business Wire 2015